The Goldman Sachs Group upgraded Tempus AI (TEM) to "Hold" from "Neutral." Overall analyst sentiment for the precision medicine company remains mixed. The consensus rating stands at "Hold." Analysts set an average price target of $69.63. This target is below the stock's recent trading price.
Tempus announced a 21.6% year-over-year revenue increase in its latest quarterly report. Revenue reached $382.49 million. The company reported an adjusted loss per share of $0.04. This loss was better than anticipated. Tempus saw growth in its oncology and data licensing segments.
However, Tempus remains unprofitable. Recent insider selling by top executives raised investor concerns. These concerns relate to the stock's valuation following a significant rally.